Objective: To describe the 1 year incidence of EPS in patients with schizophrenia newly initiated on an SGA medication within a Medicaid population
Objective: To describe the 1 year incidence of EPS in patients with schizophrenia newly initiated on an SGA medication within a Medicaid population
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.